

Note

Aryl azides as forgotten electrophiles in the Van Leusen reaction: a multicomponent transformation affording 4-tosyl-1-arylimidazoles

Cristiana Necardo, Antonella Ilenia Alfano, Erika Del Grosso, Sveva Pelliccia, Ubaldina Galli, Ettore Novellino, Fiorella Meneghetti, Mariateresa Giustiniano, and Gian Cesare Tron

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.9b02546 • Publication Date (Web): 29 Nov 2019

Downloaded from pubs.acs.org on December 2, 2019

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3 **Aryl azides as forgotten electrophiles in the Van Leusen reaction: a multicomponent**
4 **transformation affording 4-tosyl-1-arylimidazoles**
5
6
7

8
9 Cristiana Necardo,^a Antonella Ilenia Alfano,^b Erika Del Grosso,^a Sveva Pelliccia,^b Ubaldina Galli,^a
10
11 Ettore Novellino,^b Fiorella Meneghetti,^c Mariateresa Giustiniano*^b and Gian Cesare Tron*^a
12
13
14
15
16
17
18
19


20 ^a Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale “A. Avogadro”, Largo
21
22 Donegani 2, 28100 Novara, Italy.
23
24

25
26 ^b Dipartimento di Farmacia, Università degli Studi di Napoli “Federico II”, via D. Montesano 49,
27
28 80131 Napoli, Italy.
29
30

31
32 ^c Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via L. Mangiagalli 25,
33
34 20133 Milano, Italy.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 Corresponding Authors: Mariateresa Giustiniano mariateresa.giustiniano@unina.it
55
56 Gian Cesare Tron giancesare.tron@uniupo.it
57
58
59
60

TABLE OF CONTENTS



ABSTRACT

Considering aryl azides as electrophilic partners for the TosMIC mediated Van Leusen reaction, a novel multicomponent synthesis of 4-tosyl-1-arylimidazoles is reported. In this transformation, two molecules of TosMIC participate in the reaction mechanism in two different ways, with the second molecule undergoing a novel type of fragmentation resulting in the incorporation of a C-H into the final product.


1
2
3 Serendipitously obtained in low yield (14%) by irradiating tosyldiazomethane in liquid hydrogen
4 cyanide by the Dutch Professor Jan Strating and his former student Albert Van Leusen in 1967,¹
5
6 toluenesulfonylmethyl isocyanide (TosMIC) rapidly turned from a chemical curiosity to the most
7
8 important and versatile functionalized isocyanides ever synthesized.²
9

10
11
12 Indeed, in 1972 the same authors presented a safer and scalable synthetic route for TosMIC³ and in
13
14 the same year Albert Van Leusen started his independent career on TosMIC chemistry
15
16 demonstrating the versatility of this non-smelling, shelf stable isocyanide as a valuable reagent in
17
18 organic synthesis. Preparations of substituted oxazoles and thiazoles by reacting TosMIC and
19
20 carbonyl compounds⁴ or carboxymethyl dithioates,⁵ respectively, were published. Over the course
21
22 of the years, Professor Van Leusen and his group were able to expand the chemical boundaries of
23
24 TosMIC, recognizing that the consecutive presence of an isocyanide, an acidic CH, and a leaving
25
26 group allowed for unprecedented transformations with different reactants. Imidazoles, 1,2,4-triazoles,
27
28 and pyrroles could be easily obtained by reacting TosMIC with different electrophiles such as
29
30 imines,⁶ aryldiazonium salts,⁷ and Michael acceptors.⁸ Furthermore, TosMIC could also be used as
31
32 a reagent for converting a ketone to a nitrile in aprotic solvents,⁹ or as masked formaldehyde
33
34 reagent to form symmetrical and unsymmetrical ketones¹⁰ or benzyl derivatives.¹¹ The versatility of
35
36 TosMIC was then recognized by other chemists who, with their imagination and intuition, pushed
37
38 further the boundaries of its chemistry. Excellent reviews on TosMIC appeared in the literature
39
40 covering the period from 1972 to 2018.¹²
41
42
43
44
45
46

47 The most rationale use of TosMIC is to exploit its α -acidity ($pK_a = 12-14$)¹³ in order to favor the
48
49 nucleophilic attack of the TosMIC anion to an electrophile, and finally use the isocyano group as a
50
51 carbenoid to form a five-membered rings in a *5-endo trig* ring closure.¹⁴ Following this strategy,
52
53 successful examples have been reported with the following electrophiles: carbonyls, imines, carbon
54
55 disulfide, nitriles, isothiocyanates, Michael adducts, pyridine *N*-oxides, isoquinolines, acyl
56
57 chlorides, diazonium salts and ketimines. On the basis of the electrophile strength, better results
58
59
60

1
2
3 were obtained using strong bases for less electrophilic partners. Recently, the use of transition
4 metals has amplified and modified the chemical reactivity of TosMIC, opening a new chapter in its
5 already rich history. For example, the metal assisted syntheses of *E*-vinyl sulfones,¹⁵ α -sulfonated
6 ketones,¹⁶ and sulfonyl benzofurans¹⁷ have been reported.

7
8
9
10
11
12 Reflecting on the electrophiles reported in the literature able to react with the TosMIC anion, we
13 became aware that no reports on the reaction between TosMIC and aryl azides were available.
14
15 Although azides are almost always considered as 1,3-dipolar species or nitrenes precursors of via
16 thermal or photochemical degradation, the terminal nitrogen atom can be intercepted by
17 nucleophiles and azides can also be considered electrophilic reagents. Example of reactions where
18 azides behave like electrophiles are the Dimroth triazole synthesis and the Staudiger reaction.¹⁸ For
19 this reason, we decided to evaluate the reaction of TosMIC with aryl azides. As a model reaction,
20 we chose TosMIC (**1**) and phenyl azide (**2**). When the reaction was carried out in THF at room
21 temperature in the absence of a base, no reaction occurred. But when under the same reaction
22 conditions, *t*-BuOK was added, the reaction proceeded very fast, and we noticed a rapid evolution
23 of gas. The main product was isolated, and its structure unequivocally determined by single crystal
24 X-ray diffraction to be the 4-tosyl-1-phenylimidazole (**3**) obtained in 12% yield (Scheme 1).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40



53 **Scheme 1.** Reaction between TosMIC and phenyl azide affords 4-tosyl-1-phenylimidazole and
54 ORTEP¹⁹ view of **3** and the relative arbitrary atom numbering scheme (thermal ellipsoids at 40%
55 probability).
56
57
58
59
60

A literature search showed that 4-tosyl-1-arylimidazoles were already reported via different synthetic strategies. For example, they could be prepared by reacting arylazasulfones **5** with TosMIC²⁰ or via oxidation of dilithiated 1-phenyl-4-tosyl-1*H*-imidazole-5-thiol **6** with alkaline potassium ferricyanide²¹ or, finally via reaction between aryl formamidate **7** or aryl formamidines and TosMIC in the presence of sodium hydride (Figure 1).²²





Figure 1. Reported methods for the synthesis of 4-tosyl-1-arylimidazoles.

While these methods can give access to 4-tosyl-1-arylimidazoles, there are evident limitations associated with them such as the use of strong base, problems of selectivity, reaction time, required synthesis of intermediates, and use of external oxidants which can restrict the versatility of these transformations.

As the preparation of aryl azides is an easy task which does not suffer limitations, thus allowing for the preparations of any aromatic azide, this novel transformation could give access to an increased number of functionalized 4-tosyl-1-arylimidazoles not attainable with the other reported methods. For this reason, we considered this novel transformation worthy of further studies and improvements. At first, reasoning on the possible reaction mechanism, it was clear that two equivalents of TosMIC participated actively in this transformation. A possible scenario for this

1
2
3 multicomponent reaction is represented in Scheme 2. To initiate the process, the TosMIC anion
4 attacks N-3 of the azide to form intermediate **A**. Subsequently, N-1 intercepts the isocyanide in a 6
5
6 *endo-trig* cyclization to form anion **B**, which is quenched by a proton source (e.g. *tert*-butanol) to
7
8 form **C**. Due to its instability, **C** undergoes a [4+2] cycloreversion to form **D** with loss of nitrogen.
9
10 The imine of **D** then undergoes attack by a second molecules of TosMIC anion, followed by ring
11
12 closure to form **E**. At this point, after protonation, intermediate **F** regains aromaticity through a base
13
14 assisted mechanism with the expulsion of the most acidic proton and loss of hydrogen cyanide and
15
16 sulfinate. Under strong basic conditions, excess of *t*-BuOK deprotonates the newly formed
17
18 hydrogen cyanide, avoiding the release of toxic HCN. It is worth to note that the two molecules of
19
20 TosMIC participate in the reaction mechanism in two different ways, with the second molecule in
21
22 the scheme undergoing a fragmentation resulting in the incorporation of a C-H into the final
23
24 molecule. To the best of our knowledge, this mechanistic feature has never been reported for the
25
26 TosMIC reagent. HRMS infusion of the reaction mixture revealed the presence both intermediates
27
28 **A** or **B** and *p*-toluensulfonic acid, while intermediate **D** was not detectable probably due to its
29
30 instability (see supporting information).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Scheme 2. Plausible reaction pathway.

Relying on this mechanistic scenario, several reaction parameters were varied (solvent, base, temperature, reagent equivalents) in order to increase the yield and control the exothermicity of the reaction. The results are shown in the supporting information. As expected, increasing the number of TosMIC and base equivalents boosted the yield with *t*-BuOK still being the best base, since it has the possibility to exchange protons with intermediates **B** and **E**. Cooling the reaction to 0 °C before adding the base had the beneficial effect of increasing the yield. Interestingly, when a polar protic solvent (MeOH) was used, no reaction was observed after 30 minutes; aprotic solvents (DMSO, DMF) were the best choice to carry out the reaction. Best reaction conditions (DMF, 2.5 equiv. of TosMIC, 0 °C then rt, 30 minutes) increased the yield of **3** to 58%. With these optimal conditions in

hand, the substrate scope of the reaction using different aryl azides (**A-U**) and TosMIC analogues (**V-X**) (Figure 2) was evaluated, resulting in 23 additional successful examples (**8-30**) as shown in Figure 3.



Aryl azides**TosMIC analogues**

Figure 2. Building blocks used.





Figure 3. 4-arylsulfonyl-1-(hetero)arylimidazoles synthesized

1
2
3 When electron withdrawing groups (EWGs) were present on the aryl azides, the reaction afforded
4
5 higher yields. This is in line with the same observation for the Dimroth reaction, as the presence of
6
7 EWGs increase the electrophilic nature of the azide group.²³ However, the reaction was also
8
9 successful with aryl azides containing electron donating groups, with only a slight reduction in
10
11 yields, and even with sterically demanding substrates. Finally, the use of heteroaryl azides were
12
13 well tolerated, together with the use of TosMIC analogues. When two different TosMIC analogues
14
15 were used, the reaction led to both the two possible products in a 1:1 ratio. Moreover, a TosMIC
16
17 analogue substituted at the alpha position with a phenyl ring was also tested, but unfortunately, no
18
19 definite products were obtained. Notably, the reaction was very fast, with full conversion of starting
20
21 materials in less than 30 minutes. Simple column chromatography and methanol recrystallization
22
23 afforded the desired products.

24
25
26
27
28 The presented reaction does not work with aliphatic azides, vinyl azides, boronic azides, and
29
30 toluene sulphonyl azide, as we detected an inseparable reaction mixture. When acyl azides were
31
32 employed, we isolated 5-aryl-4-tosyloxazoles in high yield. This is exemplified by the reaction in
33
34 Scheme 3. In this case, acyl azide **33** behaves like an acyl chloride⁴ towards the TosMIC anion and,
35
36 after acylation of the α -carbon of TosMIC, enolization and ring closure of the isocyanide, the
37
38 corresponding 4,5-disubstituted oxazole **34** is formed.



53 **Scheme 3.** With acylazides, 5-aryl-4-tosyloxazoles are formed.

54
55
56
57
58 In conclusion, following the idea that aryl azides have never been considered as potential
59
60 electrophilic partner in the Van Leusen reaction with the anion of TosMIC, we demonstrated the

1
2
3 feasibility of this strategy, enabling the formation of 4-arylsulfonyl-1-(hetero)arylimidazoles in
4
5 good yields. In this novel multicomponent reaction, two molecules of TosMIC participate in the
6
7 reaction mechanism displaying two distinct chemical behaviors, and sulfinic acid anion and
8
9 hydrogen cyanide fragmentation of TosMIC was reported for the first time. The versatility of this
10
11 reaction associated with the ready availability of aryl azides, operational simplicity, and reduced
12
13 reaction times renders this methodology much more attractive with respect to previously reported
14
15
16
17 routes.

22 **EXPERIMENTAL SECTION**

23
24 **Solvents and Reagents.** Commercially available reagents and solvents were used without further
25
26 purification. When necessary the reactions were performed in oven-dried glassware under a positive
27
28 pressure of dry nitrogen.
29
30

31
32 **Chromatography.** Column chromatography was performed on silica gel (70–230 mesh ASTM)
33
34 using the reported eluents. Thin layer chromatography (TLC) was carried out on 5 x 20 cm plates
35
36 with a layer thickness of 0.25 mm (Silica gel 60 F254). When necessary they were developed with
37
38 KMnO_4 .
39
40

41
42 **Spectra.** Infrared spectra were recorded on a FT-IR Thermo-Nicolet Avatar spectrometer with
43
44 absorption maxima (ν_{max}) recorded in wavenumbers (cm^{-1}). ^1H and ^{13}C APT NMR were recorded
45
46 on at 400 MHz. High-resolution ESI-MS spectra were performed on a Thermo LTQ Orbitrap XL
47
48 mass spectrometer. The spectra were recorded by infusion into the ESI source using MeOH as the
49
50 solvent. Chemical shifts (δ) are reported in part per million (ppm) relative to residual solvent peak.
51
52 Melting points were determined using a Stuart Scientific SMP3 apparatus and remain uncorrected.
53
54

55
56 **General preparation of phenyl azides (A-U).** The aryl azides were readily synthesized in two
57
58 steps starting from the corresponding anilines.
59
60

Preparation of aryl azides. The corresponding aniline (5 mmol) was suspended in water (1 M, 5 mL); hydrochloric acid (2M, 2.5 mL) was added dropwise and a solution of sodium nitrite (1.1 equiv., 5.5 mmol, 379 mg) in water (3M, 1.8 mL) was added at 0°C. The reaction was stirred at 0°C for 10 minutes. A solution of sodium azide (1.1 equiv., 5.5 mmol, 358 mg) in water (6M, 0.9 mL) was added at 0°C and the reaction mixture was stirred for additional 10 minutes.

The aryl azide was extracted with dichloromethane (x3), the organic phase was washed with brine, evaporated under reduced pressure, and used without further purification in the multicomponent reaction. Phenyl azides **A-U** matched the NMR data as reported in literature (see supporting information for references)²⁴⁻⁴², while the aryl azide **S** was newly synthesized.

4-azido-1-bromo-2-chlorobenzene (S). The crude material was purified by column chromatography (*n*-hexane/ EtOAc 199:1) to give the product as yellowish solid (767 mg, 66% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, *J* = 8.8 Hz, 1H), 7.12 (d, *J_m* = 2.4 Hz, 1H), 6.80 (dd, *J₁* = 8.8 Hz, *J₂* = 2.8 Hz, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 140.5, 135.6, 134.5, 120.8, 118.6, 117.8. Mp 46-47 °C.

Preparation of benzoyl azide (33). Benzoyl chloride (5 mmol) was dissolved in acetone (1.5 M, 3.3 mL) at 0°C; a 3M solution of sodium azide (1.5 equiv., 7.5 mmol, 0.49 g) in water was added dropwise at 0°C and the reaction mixture was stirred at room temperature until the complete formation of the product as judged by TLC (typically 10 minutes).

The benzoyl azide was extracted with ethyl acetate (x3), the organic phase was washed with brine, evaporated under reduced pressure, and the crude was purified by chromatographic column. Benzoyl azide **31** matched the NMR data as reported in literature.⁴³

General preparation of 1-phenyl-4-(phenylsulfonyl)-1H-imidazoles (3, 8-32). The isocyanide (0.62 mmol, 2.5 equiv.) was dissolved in DMF (0.25 M), potassium *tert*-butoxide (0.62 mmol, 2.5 equiv., 70 mg) was added at 0 °C. After 2 minutes the aryl azide (0.25 mmol, 1 equiv.), was added

1
2
3 and the reaction mixture was stirred at 0 °C for 10 minutes and at room temperature for 20 minutes.
4
5 The reaction mixture was diluted with ethyl acetate and water. The aqueous layer was extracted 3
6
7 times with ethyl acetate, and the collected organic phases were then washed one more time with
8
9 brine. After evaporation of the solvent, the crude material was purified by column chromatography.
10
11
12
13
14
15

16 **1-phenyl-4-tosyl-1H-imidazole (3)**. The crude material was purified by column chromatography
17
18 (PE/EtOAc 8:2 and PE/EtOAc 6:4) to give the product as yellowish solid (43 mg, 58% yield). The
19
20 model reaction was then carried out at 1 mmol scale, referred to aryl azide, without noticing any
21
22 reduction in yield. ¹H NMR (400 MHz, CDCl₃) δ 7.98-7.94 (m, 3H), 7.81 (s, 1H), 7.52-7.42 (m,
23
24 3H), 7.37-7.31 (m, 4H), 2.40 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 144.3, 143.6, 137.7,
25
26 135.9, 130.2, 129.8, 128.9, 128.0, 122.2, 121.9, 21.6. IR (KBr) 3146, 3126, 2923, 1595, 1514, 1316,
27
28 1179, 1144, 1086, 763 $\nu_{\max}/\text{cm}^{-1}$; Mp 144-146 °C; MS (ESI) *m/z* (M+H)⁺ Calcd for C₁₆H₁₅N₂O₂S⁺:
29
30 299.0849; Found: 299.0844 [M+H]⁺.
31
32
33
34
35
36
37
38

39 **1-(3-fluorophenyl)-4-tosyl-1H-imidazole (8)**. The crude material was purified by column
40
41 chromatography (PE/EtOAc 8:2 and PE/EtOAc 7:3) to give the product as a light brown solid (56
42
43 mg, 71% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.97-7.94 (m, 3H), 7.82 (s, 1H), 7.52-7.47 (m, 1H),
44
45 7.32 (d, *J* = 8.0 Hz, 2H), 7.20-7.10 (m, 3H), 2.41 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 163.1
46
47 (d, *J*_{ipso} = 248.7 Hz), 144.4, 144.0, 137.5, 137.1 (d, *J*_m = 9.8 Hz), 131.8 (d, *J*_m = 9.0 Hz), 129.8, 128.1,
48
49 122.0, 117.5 (d, *J*_p = 3.3 Hz), 115.9 (d, *J*_o = 20.9 Hz), 109.6 (d, *J*_o = 25.1 Hz), 21.6. IR (KBr) 3138,
50
51 3083, 2924, 1613, 1602, 1521, 1326, 1304, 1142, 857, 694 $\nu_{\max}/\text{cm}^{-1}$; Mp 157-159 °C; MS (ESI)
52
53 *m/z* (M+H)⁺ Calcd for C₁₆H₁₄FN₂O₂S⁺: 317.0755; Found: 317.0750 [M+H]⁺.
54
55
56
57
58
59
60

1
2
3 **1-([1,1'-biphenyl]-4-yl)-4-tosyl-1*H*-imidazole (9).** The crude material was purified by column
4 chromatography (PE/EtOAc 8:2 and PE/EtOAc 7:3) to give the product as an amorphous black
5 solid (61 mg, 65% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.99-7.97 (m, 3H), 7.87 (s, 1H), 7.69 (d,
6 *J*= 8.4 Hz, 2H), 7.57 (d, *J*= 7.6 Hz, 2H), 7.47-7.36 (m, 5H), 7.31 (d, *J*= 8.0 Hz, 2H), 2.39 (s, 3H);
7 ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 144.3, 143.5, 141.9, 139.2, 137.7, 134.9, 129.8, 129.0, 128.7,
8 128.1, 128.0, 127.0, 122.2, 21.6. IR (KBr) 3120, 3057, 2918, 1595, 1525, 1488, 1319, 1183, 1145,
9 1086, 693, 602 *v*_{max}/cm⁻¹; MS (ESI) *m/z* (M+H)⁺ Calcd for C₂₂H₁₉N₂O₂S⁺: 375.1162; Found:
10 375.1158 [M+H]⁺.
11
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **1-(4-phenoxyphenyl)-4-tosyl-1*H*-imidazole (10).** The crude material was purified by column
26 chromatography (PE/EtOAc 8:2 and PE/EtOAc 7:3) to give the product as an amorphous brown
27 solid (51 mg, 52% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, *J*= 8.0 Hz, 2H), 7.89 (s, 1H), 7.76
28 (s, 1H), 7.40-7.29 (m, 6H), 7.20-7.16 (m, 1H), 7.10-7.03 (m, 4H), 2.41 (s, 3H); ¹³C{¹H} NMR (100
29 MHz, CDCl₃) δ 158.1, 156.0, 144.3, 143.4, 137.6, 130.8 (2C), 130.0, 129.7, 128.0, 124.3, 123.7,
30 122.5, 119.5, 119.4, 21.6. IR (KBr) 3155, 3134, 3121, 3054, 2922, 1588, 1519, 1489, 1312, 1243,
31 1144, 1085, 694 *v*_{max}/cm⁻¹; MS (ESI) *m/z* (M+H)⁺ Calcd for C₂₂H₁₉N₂O₃S⁺: 391.1111; Found:
32 391.1105 [M+H]⁺.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **4-tosyl-1-(3,4,5-trimethoxyphenyl)-1*H*-imidazole (11).** The crude material was purified by
49 column chromatography (PE/EtOAc 7:3 and PE/EtOAc 6:4) to give the product as an amorphous
50 black solid (59 mg, 58% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.96-7.91 (m, 3H), 7.76 (s, 1H), 7.32
51 (d, *J*= 8.0 Hz, 2H), 6.54 (s, 2H), 3.87 (s, 6H), 3.85 (s, 3H), 2.40 (s, 3H); ¹³C{¹H} NMR (100 MHz,
52 CDCl₃) δ 154.1, 144.3, 143.3, 138.4, 137.6, 131.7, 129.8, 128.0, 122.7, 100.1, 61.0, 56.4, 21.6. IR
53
54
55
56
57
58
59
60

(KBr) 3125, 2963, 2849, 1600, 1514, 1465, 1262, 1095, 1028, 801 $\nu_{\max}/\text{cm}^{-1}$; MS (ESI) m/z (M+Na)⁺ Calcd for C₁₉H₂₀N₂NaO₅S: 411.0991; Found: 411.0967 [M+Na]⁺.

4-(4-(4-tosyl-1*H*-imidazol-1-yl)phenyl)morpholine (12). The crude material was purified by column chromatography (PE/EtOAc 6:4 and PE/EtOAc 5:5) to give the product as a pink solid (38 mg, 40% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, J = 7.2 Hz, 2H), 7.85 (s, 1H), 7.71 (s, 1H), 7.32 (d, J = 7.6 Hz, 2H), 7.25-7.22 (m, 2H), 6.95 (d, J = 8.0 Hz, 2H), 3.87-3.85 (m, 4H), 3.20-3.18 (m, 4H), 2.40 (s, 3H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 151.4, 144.2, 143.1, 137.8, 129.7, 128.0, 127.9, 123.2, 116.0, 66.6, 48.7, 21.6. IR (KBr) 3148, 3128, 2954, 2813, 1528, 1450, 1303, 1237, 1137, 1116, 926, 830 $\nu_{\max}/\text{cm}^{-1}$; Mp 198-200 °C; MS (ESI) m/z (M+H)⁺ Calcd for C₂₀H₂₂N₃O₃S⁺: 384.1377; Found: 384.1371 [M+H]⁺.

1-(*p*-tolyl)-4-tosyl-1*H*-imidazole (13). The crude material was purified by column chromatography (PE/EtOAc 8:2 and PE/EtOAc 7:3) to give the product as an amorphous reddish solid (53 mg, 68% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.95 (d, J = 8.0 Hz, 2H), 7.90 (s, 1H), 7.77 (s, 1H), 7.31-7.22 (m, 6H), 2.38 (s, 6H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 144.2, 143.3, 139.0, 137.8, 137.4, 133.5, 130.7, 129.7, 128.0, 122.3, 121.8, 21.6, 21.0. IR (KBr) 3151, 3107, 3063, 2962, 2919, 1521, 1312, 1302, 1139, 1086, 816, 662 $\nu_{\max}/\text{cm}^{-1}$; MS (ESI) m/z (M+H)⁺ Calcd for C₁₇H₁₇N₂O₂S⁺: 313.1006; Found: 313.1000 [M+H]⁺.

1-(2-phenoxyphenyl)-4-tosyl-1*H*-imidazole (14). The crude material was purified by column chromatography (PE/EtOAc 8:2 and PE/EtOAc 7:3) to give the product as an amorphous brown solid (35 mg, 36% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, J = 8.0 Hz, 2H), 7.91 (s, 1H), 7.77 (s, 1H), 7.38-7.28 (m, 6H), 7.07-7.01 (m, 4H), 2.37 (s, 3H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ

1
2
3 158.0, 156.0, 144.3, 143.3, 137.7, 130.8, 130.1, 129.8, 128.0, 124.3, 123.7, 119.5, 21.6. IR (KBr)
4
5 3152, 3121, 3071, 1588, 1522, 1488, 1318, 1236, 1141, 1086, 693 v_{\max}/cm^{-1} ; MS (ESI) m/z (M+H)⁺
6
7 Calcd for C₂₂H₁₉N₂O₃S⁺: 391.1111; Found: 391.1106 [M+H]⁺.
8
9
10
11
12
13

14 **1-(4-chlorophenyl)-4-tosyl-1H-imidazole (15)**. The crude material was purified by column
15 chromatography (PE/EtOAc 9:1 and PE/EtOAc 7:3) to give the product as a light brown solid (56
16 mg, 67% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.97-7.92 (m, 3H), 7.79 (s, 1H), 7.48 (d, *J*= 8.8 Hz,
17 2H), 7.34-7.31 (m, 4H), 2.41 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 144.4, 143.9, 137.5,
18 134.8, 134.4, 130.4, 129.8, 128.0, 123.2, 122.1, 21.6. IR (KBr) 3125, 3078, 2922, 1597, 1519, 1321,
19 1140, 1083, 706, 605 v_{\max}/cm^{-1} ; Mp 173-175 °C; MS (ESI) m/z (M+H)⁺ Calcd for C₁₆H₁₄ClN₂O₂S⁺:
20 333.0460; Found: 333.0448 [M+H]⁺.
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **1-(3-bromophenyl)-4-tosyl-1H-imidazole (16)**. The crude material was purified by column
35 chromatography (PE/EtOAc 8:2 and PE/EtOAc 6:4) to give the product as an orange-pink solid (53
36 mg, 56% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.97-7.93 (m, 3H), 7.81 (s, 1H), 7.58-7.54 (m, 2H),
37 7.41-7.26 (m, 4H), 2.41 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 144.4, 144.0, 137.5, 137.0,
38 132.0, 131.5, 129.8, 128.1, 125.1, 123.7, 120.6, 21.6. IR (KBr) 3153, 3113, 3063, 2922, 1594, 1516,
39 1490, 1315, 1303, 1142, 1087, 673, 601 v_{\max}/cm^{-1} ; Mp 190-192 °C; MS (ESI) m/z (M+Na)⁺ Calcd
40 for C₁₆H₁₃BrN₂NaO₂S: 400.9758 (97.3%); Found: 400.9745 [M+Na]⁺.
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **3-(4-tosyl-1H-imidazol-1-yl)quinoline (17)**. The crude material was purified by column
55 chromatography (PE/EtOAc 6:4 and PE/EtOAc 5:5) to give the product as a light brown solid (67
56 mg, 71% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.95 (d, *J_m*= 2.4 Hz, 1H), 8.21-8.10 (m, 3H), 7.96-
57 7.89 (m, 4H), 7.80-7.76 (m, 1H), 7.67-7.63 (m, 1H), 7.31-7.29 (m, 2H), 2.38 (s, 3H); ¹³C{¹H}
58
59
60

1
2
3 NMR (100 MHz, CDCl₃) δ 147.6, 144.6, 144.2, 144.0, 137.3, 130.9, 129.8, 129.5, 129.3, 128.6,
4 128.3, 128.0 (2C), 127.2, 122.5, 21.6. IR (KBr) 3140, 3112, 3062, 2918, 1610, 1515, 1317, 1189,
5 1147, 1084, 693, 607 $\nu_{\max}/\text{cm}^{-1}$; Mp 189-191 °C; MS (ESI) m/z (M+Na)⁺ Calcd for C₁₉H₁₅N₃NaO₂S:
6 372.0783; Found: 372.0763 [M+Na]⁺.
7
8
9
10
11
12
13
14
15

16 **1-(4-fluorophenyl)-4-tosyl-1H-imidazole (18)**. The crude material was purified by column
17 chromatography (PE/EtOAc 8:2 and PE/EtOAc 7:3) to give the product as an orange solid (48 mg,
18 61% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.95 (d, J = 8.4 Hz, 2H), 7.90 (s, 1H), 7.77 (s, 1H), 7.38-
19 7.30 (m, 4H), 7.21-7.17 (m, 2H), 2.40 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 163.6, 161.1,
20 144.4, 143.7, 137.6, 132.1 (d, J_o =3.2 Hz), 129.8, 128.0, 124.1 (d, J_m = 8.6 Hz), 122.5, 117.2 (d, J_o =
21 23.1 Hz), 21.6. IR (KBr) 3138, 3089, 3066, 2962, 2922, 1525, 1326, 1261, 1142, 1088, 1020, 807,
22 694 $\nu_{\max}/\text{cm}^{-1}$; Mp 163-165 °C dec; MS (ESI) m/z (M+H)⁺ Calcd for C₁₆H₁₄FN₂O₂S⁺: 317.0755;
23 Found: 317.0750 [M+H]⁺.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **1-([1,1'-biphenyl]-2-yl)-4-tosyl-1H-imidazole (19)**. The crude material was purified by column
40 chromatography (PE/EtOAc 9:1 and PE/EtOAc 7:3) to give the product as an orange solid (23 mg,
41 25% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, J = 8.0 Hz, 2H), 7.57-7.47 (m, 3H), 7.43 (d, J =
42 5.6 Hz, 2H), 7.36-7.21 (m, 6H), 7.01 (d, J = 7.6 Hz, 2H), 2.42 (s, 3H); ¹³C{¹H} NMR (100 MHz,
43 CDCl₃) δ 144.0, 142.4, 137.9, 137.8, 136.9, 133.6, 131.5, 129.8, 129.6, 128.9, 128.8, 128.1, 127.9,
44 126.0, 124.7, 21.6. IR (KBr) 3146, 3117, 3055, 3029, 2917, 1595, 1514, 1482, 1315, 1177, 1141,
45 694, 660 $\nu_{\max}/\text{cm}^{-1}$; Mp 165-167 °C; MS (ESI) m/z (M+H)⁺ Calcd for C₂₂H₁₉N₂O₂S⁺: 375.1162;
46 Found: 375.1149 [M+H]⁺.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1-(benzo[d][1,3]dioxol-5-yl)-4-tosyl-1H-imidazole (20).** The crude material was purified by
4 column chromatography (PE/EtOAc 7:3 and PE/EtOAc 6:4) to give the product as an amorphous
5 black solid (31 mg, 36% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, *J*= 8.4 Hz, 2H), 7.83 (s,
6 1H), 7.70 (s, 1H), 7.32 (d, *J*= 8.0 Hz, 2H), 6.88-6.79 (m, 3H), 6.06 (s, 2H), 2.40 (s, 3H); ¹³C{¹H}
7 NMR (100 MHz, CDCl₃) δ 148.9, 148.2, 144.3, 143.2, 137.7, 130.1, 129.8, 128.0, 122.7, 115.9,
8 108.8, 103.9, 102.3, 21.6. IR (KBr) 3142, 2915, 1517, 1317, 1306, 1246, 1149, 1037, 691, 604
9 $\nu_{\max}/\text{cm}^{-1}$; MS (ESI) *m/z* (M+Na)⁺ Calcd for C₁₇H₁₄N₂NaO₄S: 365.0572; Found: 365.0556 [M+Na]⁺.
10
11
12
13
14
15
16
17
18
19
20
21
22

23 **4-(4-tosyl-1H-imidazol-1-yl)pyridine (21).** The crude material was purified by column
24 chromatography (PE/EtOAc 6:4 and PE/EtOAc 3:7) to give the product as a yellow solid (34 mg,
25 45% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.76-8.75 (m, 2H), 8.06 (s, 1H), 7.98-7.94 (m, 3H),
26 7.35-7.33 (m, 4H), 2.41 (s, 3H); ¹³C{¹H}¹ NMR (100 MHz, DMSO-d₆) δ 155.4, 150.8, 144.7, 143.5,
27 143.3, 138.0, 130.4, 127.9, 115.4, 22.3. IR (KBr) 3137, 2963, 2921, 1591, 1519, 1323, 1143, 1085,
28 819, 806 $\nu_{\max}/\text{cm}^{-1}$; Mp 195-197 °C; MS (ESI) *m/z* (M+H)⁺ Calcd for C₁₅H₁₄N₃O₂S⁺: 300.0802;
29 Found: 300.0794 [M+H]⁺.
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **1-(4-nitrophenyl)-4-tosyl-1H-imidazole (22).** The crude material was purified by column
44 chromatography (*n*-hexane/ EtOAc 6:4) to give the product as a yellowish solid (59 mg, 69% yield).
45 ¹H NMR (400 MHz, CDCl₃) δ 8.42 (d, *J*= 9.2 Hz, 2H), 8.02 (d, *J_m*= 1.6 Hz, 1H), 7.98 (d, *J*= 8.4 Hz,
46 2H), 7.92 (d, *J_m*= 1.2 Hz, 1H), 7.59 (d, *J*= 9.2 Hz, 2H), 7.35 (d, *J*= 8.0 Hz, 2H), 2.43 (s, 3H);
47 ¹³C{¹H}¹ NMR (100 MHz, CDCl₃) δ 145.1, 144.7, 140.5, 137.1, 129.9, 128.2, 126.0, 122.0, 110.0,
48 21.6. IR (KBr) 3132, 2922, 2853, 1594, 1518, 1311, 1287, 1140, 1077, 853, 603, 534 $\nu_{\max}/\text{cm}^{-1}$; Mp
49 228-229 °C; MS (ESI) *m/z* (M+H)⁺ Calcd for C₁₆H₁₄N₃O₄S⁺: 344.0700; Found: 344.0693 [M+H]⁺.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1-(3,5-dichlorophenyl)-4-tosyl-1H-imidazole (23).** The crude material was purified by column
4 chromatography (*n*-hexane/ EtOAc 8:2) to give the product as a yellowish solid (52 mg, 57% yield).
5
6
7 ¹H NMR (400 MHz, CDCl₃) δ 8.34-8.32 (m, 1H), 8.28 (s, 1H), 8.01-7.98 (m, 2H), 7.90 (s, 1H),
8 7.76-7.75 (m, 2H), 7.35 (d, *J* = 8.4 Hz, 2H), 2.43 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ
9 144.6, 144.5, 137.4, 137.3, 136.7, 129.8, 129.0, 128.1, 121.8, 120.5, 21.6. IR (KBr) 3070, 2920,
10 2851, 1589, 1573, 1432, 1303, 1141, 1084, 799, 665, 599, 532 *v*_{max}/cm⁻¹; Mp 209-210 °C; MS (ESI)
11 *m/z* (M+H)⁺ Calcd for C₁₆H₁₃Cl₂N₂O₂S⁺: 367.0070; Found: 367.0064 [M+H]⁺.
12
13
14
15
16
17
18
19
20
21
22

23 **1-(3,4-dimethoxyphenyl)-4-tosyl-1H-imidazole (24).** The crude material was purified by column
24 chromatography (*n*-hexane/ EtOAc 8:2) to give the product as a brownish solid (60 mg, 67% yield).
25
26
27 ¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, *J* = 8.0 Hz, 2H), 7.88 (d, *J*_{*m*} = 1.2 Hz, 1H), 7.74 (d, *J*_{*m*} = 1.2
28 Hz, 1H), 7.32 (d, *J* = 8.0 Hz, 2H), 6.94-6.89 (m, 2H), 6.82 (s, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 2.40 (s,
29 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 150.0, 149.5, 144.2, 143.1, 137.8, 129.7, 129.2, 128.0,
30 122.8, 114.5, 111.6, 106.2, 56.2, 21.6. IR (KBr) 3160, 2921, 2852, 1600, 1517, 1442, 1236, 1136,
31 1082, 1025, 662, 599, 536 *v*_{max}/cm⁻¹; Mp 130-131 °C; MS (ESI) *m/z* (M+H)⁺ Calcd for
32 C₁₈H₁₉N₂O₄S⁺: 359.1061; Found: 359.1057 [M+H]⁺.
33
34
35
36
37
38
39
40
41
42
43
44

45 **1-(4-bromo-3-chlorophenyl)-4-tosyl-1H-imidazole (25).** The crude material was purified by
46 column chromatography (*n*-hexane/ EtOAc 8:2) to give the product as a brown to red solid (93mg,
47 90% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.68 (s, 1H), 8.48 (s, 1H), 8.16 (d, *J*_{*m*} = 2.4 Hz, 1H),
48 7.92 (d, *J* = 8.8 Hz, 1H), 7.81 (d, *J* = 8.0 Hz, 2H), 7.70 (dd, *J*_{*a*} = 8.4 Hz, *J*_{*b*} = 2.4 Hz, 1H), 7.41 (d, *J* =
49 7.6 Hz, 2H), 2.36 (s, 3H); ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 144.6, 142.6, 138.7, 138.3,
50 136.5, 135.2, 134.8, 130.3, 127.8, 123.5, 121.8, 121.1, 21.5. IR (KBr) 3111, 2922, 2852, 1592,
51
52
53
54
55
56
57
58
59
60

1
2
3 1513, 1463, 1313, 1138, 1084, 810, 634, 585, 532 $\nu_{\max}/\text{cm}^{-1}$; Mp 183-184 °C; MS (ESI) m/z (M+H)⁺
4
5 Calcd for C₁₆H₁₃BrClN₂O₂S⁺: (97%) 412.9544; Found: 412.9536 [M+H]⁺.
6
7
8
9

10
11 **1-(3,5-dimethoxyphenyl)-4-tosyl-1H-imidazole (26)**. The crude material was purified by column
12 chromatography (*n*-hexane/ EtOAc 8:2) to give the product as brownish oil (45 mg, 50% yield). ¹H
13 NMR (400 MHz, CDCl₃) δ 7.95 (d, J = 7.6 Hz, 2H), 7.88 (s, 1H), 7.73 (s, 1H), 7.31 (d, J = 7.6 Hz,
14 2H), 6.91-6.83 (m, 3H), 3.90 (s, 6H), 2.39 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 150.0,
15 149.5, 144.2, 143.1, 137.7, 129.7, 129.2, 128.0, 122.8, 114.5, 111.6, 106.2, 56.2, 21.6. IR (KBr)
16 3124, 2924, 2838, 1599, 1517, 1315, 1235, 1136, 1084, 1020, 660, 597, 534 $\nu_{\max}/\text{cm}^{-1}$; MS (ESI)
17 m/z (M+H)⁺ Calcd for C₁₈H₁₉N₂O₄S⁺: 359.1061; Found: 359.1053 [M+H]⁺.
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **1-(2-iodophenyl)-4-tosyl-1H-imidazole (27)**. The crude material was purified by column
32 chromatography (*n*-hexane/ EtOAc 8:2) to give the product as a yellow solid (39 mg, 37% yield).
33 ¹H NMR (400 MHz, CDCl₃) δ 7.99-7.97 (m, 3H), 7.77 (d, J_m = 1.2 Hz, 1H), 7.61 (d, J_m = 1.2 Hz,
34 1H), 7.50-7.46 (m, 1H), 7.35-7.21 (m, 4H), 2.42 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ
35 144.2, 142.9, 140.4, 139.1, 138.7, 137.7, 131.4, 129.7, 129.6, 128.0, 127.6, 124.4, 95.1, 21.6. IR
36 (KBr) 3159, 3106, 2921, 2851, 1511, 1312, 1139, 1084, 766, 688, 660, 602, 533 $\nu_{\max}/\text{cm}^{-1}$; Mp 180-
37 181 °C; MS (ESI) m/z (M+H)⁺ Calcd for C₁₆H₁₄IN₂O₂S⁺: 424.9816; Found: 424.9806 [M+H]⁺.
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **1-(3,5-dichlorophenyl)-4-(naphthalen-2-ylsulfonyl)-1H-imidazole (28)**. The crude material was
52 purified by column chromatography (*n*-hexane/ EtOAc 8:2) to give the product as a yellowish solid
53 (59 mg, 58.5% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.68 (s, 1H), 8.03-7.81 (m, 6H), 7.64-7.58 (m,
54 2H), 7.43 (s, 1H), 7.31 (s, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 144.2, 137.4, 137.1, 136.7,
55 135.2, 132.2, 129.7, 129.5 (2C), 129.2, 129.1, 127.9, 127.5, 122.9, 122.1, 120.6. IR (KBr) 3127,
56
57
58
59
60

1
2
3 2922, 1583, 1518, 1311, 1144, 1124, 1072, 852, 751, 682, 665, 588 $\nu_{\max}/\text{cm}^{-1}$; Mp 212-213 °C; MS
4
5 (ESI) m/z (M+H)⁺ Calcd for C₁₉H₁₃Cl₂N₂O₂S⁺: 403.0070; Found: 403.0062 [M+H]⁺.
6
7
8
9

10
11 **4-(naphthalen-2-ylsulfonyl)-1-(3-nitrophenyl)-1H-imidazole (29)**. The crude material was
12 purified by column chromatography (*n*-hexane/ EtOAc 8:2) to give the product as a brownish solid
13 (58 mg, 61% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.88 (s, 1H), 8.65-8.60 (m, 3H), 8.20-8.10
14 (m, 4H), 8.01-7.63 (m, 5H); ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 148.9, 142.4, 139.1, 138.1,
15 137.0, 135.0, 132.1, 131.7, 130.0, 129.9, 129.7, 129.0, 128.3, 128.2, 128.1, 124.1, 123.1, 116.8. IR
16 (KBr) 3152, 3121, 1535, 1518, 1346, 1318, 1143, 1125, 1070, 737, 662, 537 $\nu_{\max}/\text{cm}^{-1}$; Mp 163-
17 164°C; MS (ESI) m/z (M+Na)⁺ Calcd for C₁₉H₁₃N₃NaO₄S: 402.0524; Found: 402.0516 [M+Na]⁺.
18
19
20
21
22
23
24
25
26
27

28
29
30
31 **4-((4-methoxyphenyl)sulfonyl)-1-(3-nitrophenyl)-1H-imidazole (30)**. The crude material was
32 purified by column chromatography (*n*-hexane/ EtOAc 6:4) to give the product as a yellow to
33 orange solid (29 mg, 32% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.75 (s, 1H), 8.62 (s, 1H), 8.56
34 (s, 1H), 8.24-8.19 (m, 2H), 7.88-7.78 (m, 3H), 7.13-7.11 (m, 2H), 3.81 (s, 3H); ¹³C{¹H} NMR (100
35 MHz, CDCl₃) δ 163.7, 149.1, 145.1, 136.9, 131.6, 131.5, 130.4, 127.4, 123.4, 121.4, 117.0, 114.5,
36 55.7. IR (KBr) 3110, 2921, 2851, 1591, 1525, 1348, 1298, 1256, 1135, 737, 673, 600, 545 $\nu_{\max}/\text{cm}^{-1}$;
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4-((4-bromophenyl)sulfonyl)-1-(3,5-dimethoxyphenyl)-1H-imidazole (31). The crude material
was purified by column chromatography (*n*-hexane/ EtOAc 6:4) to give the product as a yellowish
amorphous solid (29 mg, 27% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.98 (d, J = 8.8 Hz, 2H), 7.92
(d, J_m = 1.2 Hz, 1H), 7.78 (d, J_m = 1.6 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 6.95-6.94 (m, 2H), 6.85 (d,

$J_m = 2.0$ Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 150.0, 149.7, 142.4, 139.8, 138.0, 132.4, 129.6, 129.1, 128.6, 123.3, 114.6, 111.6, 106.3, 56.3, 56.2. IR (KBr) 3087, 2925, 2022, 1516, 1236, 1064, 1008, 856 $\nu_{\text{max}}/\text{cm}^{-1}$; MS (ESI) m/z (M+H)⁺ Calcd for $\text{C}_{17}\text{H}_{16}\text{BrN}_2\text{O}_4\text{S}^+$: 423.0009; Found: 423.0010 [M+H]⁺.

4-((4-bromophenyl)sulfonyl)-1-(3,5-dichlorophenyl)-1H-imidazole (32). The crude material was purified by column chromatography (*n*-hexane/ EtOAc 9:1) to give the product as a yellowish amorphous solid (89 mg, 82% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.98-7.95 (m, 3H), 7.85 (s, 1H), 7.71 (d, $J = 8.4$ Hz, 2H), 7.49 (s, 1H), 7.34-7.37 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 143.8, 139.3, 137.3, 137.2, 136.8, 132.5, 129.6, 129.2, 128.9, 123.0, 122.3, 120.6. IR (KBr) 3135, 2922, 2230, 1571, 1432, 1313, 1140, 1064, 742, 628 $\nu_{\text{max}}/\text{cm}^{-1}$; MS (ESI) m/z (M+H)⁺ Calcd for $\text{C}_{15}\text{H}_{10}\text{BrCl}_2\text{N}_2\text{O}_2\text{S}^+$: 430.9018; Found: 430.9026 [M+H]⁺.

5-phenyl-4-tosyloxazole (34). The crude material was purified by column chromatography (PE/EtOAc 9.5:0.5 and PE/EtOAc 8:2) to give the product as a pink solid (61 mg, 75% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.98-7.85 (m, 5H), 7.51-7.50 (m, 3H), 7.31 (d, $J = 8.4$ Hz, 2H), 2.41 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 152.7, 149.2, 145.0, 137.1, 135.6, 130.9, 129.8, 129.0, 128.6, 128.2, 125.5, 21.7. IR (KBr) 3143, 2963, 2922, 1595, 1512, 1313, 1263, 1144, 1112, 1032, 812, 671 $\nu_{\text{max}}/\text{cm}^{-1}$; Mp 133-135 °C dec.; MS (ESI) m/z (M+H)⁺ Calcd for $\text{C}_{16}\text{H}_{14}\text{NO}_3\text{S}^+$: 300.0689; Found: 300.0688 [M+H]⁺.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website.

1
2
3 Table with the optimization reaction conditions, Spectroscopic data, HRMS spectra of reaction
4 mixture, Crystallographic description of **3**, Copies of ¹H and ¹³C spectra, (PDF)
5
6
7

8 Cif file of **3** (CCDC number: 1884065) (PDF)
9
10
11
12
13

14 AUTHOR INFORMATION

15 16 17 Corresponding Authors

18 * E-mail: mariateresa.giustiniano@unina.it;
19
20

21
22
23
24 giancesare.tron@uniupo.it
25
26
27
28

29 ACKNOWLEDGMENTS

30
31 Financial support from Università del Piemonte Orientale, Novara and Università degli Studi
32 “Federico II” Napoli, Italy is acknowledged.
33
34
35
36
37
38

39 REFERENCES

- 40
41
42
43 (1) Van Leusen, A. M.; Strating, J. Chemistry of sulfonyldiazomethanes *Q. Rep. Sulfur Chem*
44 1970, 5(1), 67-78).
45
46
47
48 (2) Giustiniano, M.; Basso, A.; Mercalli, V.; Massarotti, A.; Novellino, E.; Tron, G.C.; Zhu, J. To
49 each is own: isonitriles for all flavors. Functionalized isocyanides as valuable tools in organic
50 synthesis. *Chem. Soc. Rev.* **2017**, 46, 1295-1357.
51
52
53
54 3) (a) Van Leusen, A. M.; Boerma, G. J. M.; Helmholtz, R. B.; Siderius, H.; Strating, J. Chemistry
55 of sulfonylmethylisocyanides. Simple synthetic approaches to a new versatile chemical building
56
57
58
59
60

1
2
3 block *Tetrahedron Lett.* **1972**, *23*, 2367-2368. (b) Hoogenboom, B. E.; Oldenzien, O. H.; van
4
5 Leusen, A. M. *p*-Tolylsulfonylmethyl isocyanide *Org. Synth.* **1977**, *57*, 102-106.

6
7
8 4) Van Leusen, A. M.; Hoogenboom, B. E.; Siderius, H. Novel and efficient synthesis of oxazoles
9
10 from tosylmethyl isocyanide and carbonyl compounds *Tetrahedron Lett.* **1972**, *23*, 2369-2372.

11
12
13 5) Oldenzien, O. H.; Van Leusen, A. M. Chemistry of sulfonylmethylisocyanides. 4. New synthesis
14
15 of thiazoles from tosylmethylisocyanide and carboxymethyl dithioates *Tetrahedron Lett.* **1972**, *27*,
16
17 2777-2778.

18
19
20 6) Van Leusen, A. M.; Wildeman, Jurjen; Oldenzien, O. H. Chemistry of sulfonylmethyl
21
22 isocyanides. 12. Base-induced cycloaddition of sulfonylmethyl isocyanides to carbon,nitrogen
23
24 double bonds. Synthesis of 1,5-disubstituted and 1,4,5-trisubstituted imidazoles from aldimines and
25
26 imidoyl chlorides *J. Org. Chem.* **1977**, *42*, 1153-1159.

27
28
29 7) Van Leusen, A. M.; Hoogenboom, B. E.; Houwing, H. A. Chemistry of sulfonylmethyl
30
31 isocyanides. 11. Synthesis of 1,2,4-triazoles from tosylmethyl isocyanide and aryldiazonium
32
33 compounds *J. Org. Chem.* **1976**, *41*, 711-713.

34
35
36 8) Van Leusen, A. M.; Siderius, H.; Hoogenboom, B. E.; Van Leusen, D. Chemistry of
37
38 sulfonylmethyl isocyanides. 6. New and simple synthesis of the pyrrole ring system from Michael
39
40 acceptors and (*p*-tolylsulfonyl)methyl isocyanide *Tetrahedron Lett.* **1972**, *52*, 5337-5440.

41
42
43 9) (a) Oldenzien, O. H.; Van Leusen, A. M. Chemistry of sulfonylmethyl isocyanides. 7. Synthetic
44
45 method for direct conversion of ketones into cyanides. Introduction of a one carbon unit
46
47 *Tetrahedron Lett.* **1973**, *16*, 1357-1360. (b) Oldenzien, O. H.; Van Leusen, D.; Van Leusen, A. M.
48
49 Chemistry of sulfonylmethyl isocyanides. 13. A general one-step synthesis of nitriles from ketones
50
51 using tosylmethyl isocyanide. Introduction of a one-carbon unit *J. Org. Chem.* **1977**, *42*, 3114-3118.
52
53
54
55
56
57
58
59
60

- 1
2
3 10) Possel, O.; Van Leusen, A. M. Chemistry of sulfonylmethyl isocyanides. 16.
4 Tolylsulfonylmethyl isocyanide employed in a novel synthesis of ketones. A new masked
5 formaldehyde reagent *Tetrahedron Lett.* **1977**, *48*, 4229-4232.
6
7
8
9
10
11 11) Van Leusen, D.; Van Leusen, A. M. Chemistry of sulfonylmethyl isocyanides 17. A new
12 synthesis of symmetrical and unsymmetrical α -diketones through α -isocyano- α -tolylsulfonyl ketones
13 *Tetrahedron Lett.* **1977**, *48*, 4233-4236.
14
15
16
17
18
19 12) (a) Van leusen, D.; Van Leusen, A. M. Synthetic uses of tosylmethyl isocyanide (TosMIC) *Org*
20 *React.* **2001**, *57*, 417-666. (b) Di Santo, R.; Massa, S.; Artico, M.; Synthesis of biologically active
21 azoles via TosMIC *Il Farmaco* **1993**, *48*, 209-229. (c) Lamberth, C. 4-Toluenesulfonylmethyl
22 isocyanide (TosMIC). A versatile formaldehyde equivalent with reversed polarity *J. Prakt. Chem.*
23 **1998**, *340*, 483-485. (d) Tandon, V.K.; Rai, S. *p*-Toluenesulfonylmethyl Isocyanide: a Versatile
24 Synthone in Organic Chemistry *Sulfur reports* **2003**, *24*, 307-385. (e) Kaur, T.; Wadhwa, P.; Sharma,
25 A. Arylsulfonylmethyl isocyanides: a novel paradigm in organic synthesis *RCS Adv.* **2015**, *5*,
26 52769-52787. (f) Mathiyazhagan, A. D.; Anilkumar, G. Recent advances and applications of *p*-
27 toluenesulfonylmethyl isocyanide (TosMIC) *Org. Biomol. Chem.* **2019**, *17*, 6735-6747.
28
29
30
31
32
33
34
35
36
37
38
39
40 13) Eger, W. A.; Grange, R. L.; Schill, H.; Goumont, R.; Clark, T.; Williams, C. M. Understanding
41 the Reactivity of Acyl Anion Equivalents: The Epoxide Ring Opening Case *Eur. J. Org. Chem.*
42 **2011**, 2548-2553.
43
44
45
46
47
48 14) This is an unsolved topic. Indeed, it is also possible to consider the isocyanide in its zwitterionic
49 form and in this case the cyclization would be an allowed *5-endo dig* closure. In this case remains
50 the problem due to the partial negative charge on the isocyanide carbon atom. Anyway, although
51 considered unfavorable in the first Baldwin rules, examples of successful *5-endo dig* have been
52 reported and an explanation has been proposed see: Gilmore, K.; Mohamed, R. K.; Alabugin, I. V.
53 The Baldwin rules: revised and extended *WIREs Comput. Mol. Sci.* **2016**, *6*, 487-514.
54
55
56
57
58
59
60

- 1
2
3 15) Phanindrudu, M.; Tiwari, D. K.; Sridhar, B.; Likhar, P. R.; Tiwari, D. K. Magnetically
4 separable nano-copper catalyzed unprecedented stereoselective synthesis of *E*-vinyl sulfones from
5 tosylmethyl isocyanide and alkynes: TosMIC as a source of the sulfonyl group *Org. Chem. Front.*
6 **2016**, *3*, 795-798.
7
8
9
10
11
12
13 16) Chen, J.; Guo, W.; Wang, Z.; Hu, L.; Chen, F.; Xia, Y. Unexpected Role of *p*-
14 Toluenesulfonylmethyl Isocyanide as a Sulfonylating Agent in Reactions with α -Bromocarbonyl
15 Compounds *J. Org. Chem.* **2016**, *81*, 5504-5512.
16
17
18
19
20
21 17) Liu, J.; Liu, Z.; Liao, P.; Bi, Z. Modular Synthesis of Sulfonyl Benzoheteroles by Silver-
22 Catalyzed Heteroaromatization of Propargylic Alcohols with *p*-Toluenesulfonylmethyl Isocyanide
23 (TosMIC): Dual Roles of TosMIC *Org. Lett.* **2014**, *16*, 6204-6207.
24
25
26
27
28
29 18) Organic Syntheses Based On Name Reactions: A Practical Guide To 750 Transformations, 3Rd
30 Edition by Hassner, Elsevier, **2013** and references herein cited.
31
32
33
34 19) Dell'Erba, C.; Novi, M.; Petrillo, G.; Tavani, C. Reactions of arylazosulfones with the
35 conjugate bases of (*tert*-butoxycarbonyl)methyl and tosylmethyl isocyanide. Synthesis of
36 substituted 1-arylimidazoles *Tetrahedron* **1997**, *53*, 2125-2136.
37
38
39
40
41
42 20) Van Nispen, S. P. J. M.; Bregman, J. H.; Van Engen, D. G.; Van Leusen, A. M. Synthesis of
43 thiazoles and imidazoles from isothiocyanates and tosylmethyl isocyanide. Base-induced ring
44 transformation of 5-amino-1,3-thiazoles to imidazole-5-thiols *Recueil: Journal of the Royal*
45 *Netherlands Chemical Society* **1982**, *101*, 28-34.
46
47
48
49
50
51
52 21) (a) Taylor, E. C.; LaMattina, J. L.; Tseng, C. P. Nucleophilic displacement of primary amino
53 groups via 1-substituted 4-tosylimidazoles *J. Org. Chem.* **1982**, *47*, 2043-2047. (b) Gomez-Garcia,
54 O.; Salgado-Zamora, H.; Reyes-Arellano, A.; Campos-Aldrete, E.; Peralta-Cruz, J. Reaction of
55 Tosylmethyl Isocyanide with N-Heteroaryl Formamidines: an Alternative Approach to the
56 Synthesis of N-Heteroaryl Tosylimidazoles *Bull. Korean Chem. Soc.* **2013**, *34*, 2807-2810.
57
58
59
60

- 1
2
3 22) Intermediate **C** and **D** are unstable, and we were not able to isolate them or to identify them
4 using HPLC-DAD and UHPLC-HRMS for a real-time monitoring of the reaction, while it was
5 easily detected the presence of *p*-toluensulfonic acid.
6
7
8
9
10
11 23) Chapter 5 pag. 269-277 in “Name reactions in heterocyclic Chemistry II” Ed. Jie Jack Lee,
12
13 **2011** Wiley.
14
15
16 24) Dai, Z.-C.; Chen, Y.-F.; Zhang, M.; Li, S.-K.; Yang, T.-T.; Shen, L.; Wang, J.-X.; Qian, S.-S.;
17
18 Zhu, H.-L.; Ye, Y.-H. Synthesis and antifungal activity of 1,2,3-triazole phenylhydrazone
19
20 derivatives *Org. Biomol. Chem.* **2015**, *13*, 477-486.
21
22
23
24 25) Kutonova, K. V.; Trusova, M. E.; Postnikov, P. S.; Filimonov, V. D.; Parello, J. A simple and
25
26 effective synthesis of aryl azides via arenediazonium tosylates *Synthesis* **2013**, *45*, 2706-2710.
27
28
29
30 26) Mamidyala, S. K.; Cooper, M. A. Probing the reactivity of *o*-phthalaldehydic acid/methyl ester:
31
32 synthesis of *N*-isoindolinones and 3-arylamino-phthalides *Chem. Commun.* **2013**, *49*, 8407-8409.
33
34
35 27) Kumar, S.; Pathania, A. S.; Satti, N. K.; Dutt, P.; Sharma, N.; Mallik, F. A.; Ali, A. Synthetic
36
37 modification of hydroxychavicol by Mannich reaction and alkyne-azide cycloaddition derivatives
38
39 depicting cytotoxic potential *Eur. J. Med. Chem.* **2015**, *92*, 236-245.
40
41
42
43 28) Li, Y.-T.; Wang, J.-H.; Pan, C.-W.; Meng, F.-F.; Chu, X.-Q.; Ding, Y.-h.; Qu, W.-Z.; Li, H.-y.;
44
45 Yang, C.; Zhang, Q.; Bai, C.-G.; Chen, Y. Syntheses and biological evaluation of 1,2,3-triazole and
46
47 1,3,4-oxadiazole derivatives of imatinib *Bioorg. Med. Chem. Lett.* **2016**, *26*, 1419-1427.
48
49
50
51 29) Maruani, A.; Alom, S.; Canavelli, P.; Lee, M. T. W.; Morgan, R. E.; Chudasama, V.; Caddick,
52
53 S. A mild TCEP-based *para*-azidobenzyl cleavage strategy to transform reversible cysteine thiol
54
55 labelling reagents into irreversible conjugates *Chem. Commun.* **2015**, *51*, 5279-5282.
56
57
58
59 30) Knepper, K.; Lormann, M. E. P.; Brase, S. Efficient Synthesis of Highly Substituted Diaryl
60
Ethers on Solid Supports Using the Ullmann Reaction *J. Comb. Chem.* **2004**, *6*, 460-463.

- 1
2
3 31) Bertrand, H. C.; Schaap, M.; Baird, L.; Georgakopoulos, N. D.; Fowkes, A.; Thiollier, C.;
4
5 Kachi, H.; Dinkova-Kostova, A. T.; Wells, G. Design, Synthesis, and Evaluation of Triazole
6
7 Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1-Nrf2 Protein-Protein
8
9 Interaction *J. Med. Chem.* **2015**, *58*, 7186-7194.
10
11
12
13 32) Bou-Hamdan, F. R.; Levesque, F.; O'Brien, A. G.; Seeberger, P. H. Continuous flow photolysis
14
15 of aryl azides: preparation of 3H-azepinones *Beilstein J. Org. Chem.* **2011**, *7*, 1124-1129.
16
17
18 33) Yang, L.; Zhang, Y.; Zou, X.; Lu, H.; Li, G. Visible-light-promoted intramolecular C-H
19
20 amination in aqueous solution: synthesis of carbazoles *Green Chem.* **2018**, *20*, 1362-1366.
21
22
23
24 34) Dangroo, N. A.; Singh, J.; Dar, A. A.; Gupta, N.; Chinthakindi, P. K.; Kaul, A.; Khuroo, M. A.;
25
26 Sangwan, P. L. Synthesis of α -santonin derived acetyl santonous acid triazole derivatives and their
27
28 bioevaluation for T and B-cell proliferation *Eur. J. Med. Chem.* **2016**, *120*, 160-169.
29
30
31 35) Jia, Z.; Zhu, Q. Click' assembly of selective inhibitors for MAO-A *Bioorg. Med. Chem. Lett.*
32
33 **2010**, *20*, 6222-6225.
34
35
36
37 36) Sebest, F.; Casarrubios, L.; Rzepa, H. S.; White, A. J. P.; Díez-González, S. Thermal azide-
38
39 alkene cycloaddition reactions: straightforward multi-gram access to Δ^2 -1,2,3-triazolines in deep
40
41 eutectic solvents *Green Chem.* **2018**, *20*, 4023-4035.
42
43
44
45 37) Chandna, N.; Kaur, F.; Kumar, S.; Jain, N. Glucose promoted facile reduction of azides to
46
47 amines under aqueous alkaline conditions *Green Chem.* **2017**, *19*, 4268-4271.
48
49
50 38) Wang, S.; Jia, K.; Cheng, J.; Chen, Y.; Yuan, Y. Dual roles of substituted thiourea as reductant
51
52 and ligand in CuAAC reaction *Tetrahedron Lett.* **2017**, *58*, 3717-3721.
53
54
55
56 39) Utsintong, M.; Massarotti, A.; Caldarelli, A.; Theeramunkong, S. Parallel Synthesis of "Click"
57
58 Chalcones as Antitubulin Agents *Med. Chem.* **2013**, *9*, 510-516.
59
60

- 1
2
3 40) Yamamoto, K.; Bruun, T.; Kim, J. Y.; Zhang, L.; Lautens, M. A New Multicomponent
4 Multicatalyst Reaction (MC)²R: Chemoselective Cycloaddition and Latent Catalyst Activation for
5 the Synthesis of Fully Substituted 1,2,3-Triazoles *Org. Lett.* **2016**, *18*, 2644-2647.
6
7
8
9
10
11 41) Zhang, Z.; Xiao, F.; Huang, B.; Hu, J.; Fu, B.; Zhang, Z. Cyclization of Alkyne–Azide with
12 Isonitrile/CO via Self-Relay Rhodium Catalysis *Org. Lett.* **2016**, *18*, 909-911.
13
14
15
16 42) Das, D.; Samanta, R. Iridium(III)-Catalyzed Regiocontrolled Direct Amidation of Isoquinolones
17 and Pyridones *Adv. Synth. Catal.* **2018**, *360*, 379-384.
18
19
20
21 43) Katritzky, A. R.; Widyan, K.; Kirichenko, K. Preparation of Polyfunctional Acyl Azides *J. Org.*
22 *Chem.* **2007**, *72*, 5802-5804.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60